共 50 条
- [31] Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphomaBone Marrow Transplantation, 2020, 55 : 1184 - 1187Brian T. HillZachary J. RobertsAllen XueJohn M. RossiMitchell R. Smith
- [32] Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphomaBONE MARROW TRANSPLANTATION, 2020, 55 (06) : 1184 - 1187Hill, Brian T.Roberts, Zachary J.Xue, AllenRossi, John M.Smith, Mitchell R.
- [33] Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell TherapyBLOOD, 2017, 130Chong, Elise A.Melenhorst, J. JosephSvoboda, JakubNasta, Sunita DwivedyLandsburg, Daniel J.Mato, Anthony R.Tian, LifengParakandi, HaritLacey, Simon F.June, Carl H.Schuster, Stephen J.
- [34] Phase 1 Dose Escalation Study of Pembrolizumab in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Large B-Cell or Follicular Lymphoma Following Progression after Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell TherapyBLOOD, 2023, 142McCurry, DustinWestin, JasonFeng, LeiAhmed, SairahNair, RanjitSteiner, Raphael EricWynn, LaurenThomas, JenniferDsouza, Ly HuynhSamaniego, FelipeNeelapu, Sattva S.Nastoupil, Loretta J.
- [35] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 41 - 43Wang, MichaelMunoz, JavierGoy, AndreLocke, FrederickJacobson, CaronHill, BrianTimmerman, JohnHolmes, HoustonJaglowski, SamanthaFlinn, IanMcSweeney, PeterMiklos, DavidPagel, JohnKersten, Marie JosePeng, WeiminZheng, LianqingRossi, JohnJain, RajulRao, AratiReagan, Patrick
- [36] Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1275 - +Mi, Jian-QingZhao, WanhongJing, HongmeiFu, WeijunHu, JiandaChen, LijuanZhang, YiwenYao, DanChen, DianaSchecter, Jordan M.Yang, FanTian, XiaochenSun, HuabinZhuang, Sen HongRen, JimmyFan, XiaohuJin, JieNiu, TingChen, Sai-Juan
- [37] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyLANCET, 2021, 398 (10297): : 314 - 324Berdeja, Jesus G.Madduri, DeepuUsmani, Saad Z.Jakubowiak, AndrzejAgha, MounzerCohen, Adam D.Stewart, A. KeithHari, ParameswaranHtut, MyoLesokhin, AlexanderDeol, AbhinavMunshi, Nikhil C.O'Donnell, ElizabethAvigan, DavidSingh, IndrajeetZudaire, EnriqueYeh, Tzu-MinAllred, Alicia J.Olyslager, YunsiBanerjee, ArnobJackson, Carolyn C.Goldberg, Jenna D.Schecter, Jordan M.Deraedt, WilliamZhuang, Sen HongInfante, JeffreyGeng, DongWu, XiaolingCarrasco-Alfonso, Marlene J.Akram, MuhammadHossain, FarahRizvi, SyedFan, FrankLin, YiMartin, ThomasJagannath, Sundar
- [38] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2MOLECULAR THERAPY, 2020, 28 (04) : 573 - 573Wang, MichaelMunoz, JavierGoy, AndreLocke, Frederick L.Jacobson, Caron A.Hill, Brian T.Timmerman, John M.Holmes, HoustonJaglowski, SamanthaFlinn, Ian W.McSweeney, Peter A.Miklos, David B.Pagel, John M.Kersten, Marie JosePeng, WeiminZheng, LianqingRossi, John M.Jain, Rajul K.Rao, Arati V.Reagan, Patrick M.
- [39] A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaJOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11Zhao, Wan-HongLiu, JieWang, Bai-YanChen, Yin-XiaCao, Xing-MeiYang, YunZhang, Yi-LinWang, Fang-XiaZhang, Peng-YuLei, BoGu, Liu-FangWang, Jian-LiYang, NanZhang, RuZhang, HuiShen, YingXu, Ju Bai YanWang, Xu-GengZhang, Rui-LiWei, Li-LiLi, Zong-FangLi, Zhen-ZhenGeng, YanHe, QianZhuang, Qiu-ChuanFan, Xiao-HuHe, Ai-LiZhang, Wang-Gang
- [40] Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaBLOOD, 2018, 132Wierda, William G.Bishop, Michael R.Oluwole, Olalekan O.Logan, Aaron C.Baer, Maria R.Donnellan, William B.O'Dwyer, Kristen M.Castro, Januario E.Schiller, Gary J.Holmes, HoustonAbedi, MehrdadGhobadi, ArminArellano, Martha L.Malone, Adriana K.Pagel, John M.Mardiros, ArmenShen, TongVezan, RemusJain, Rajul K.Shah, Bijal D.